Barclays reiterates Tesla stock Equalweight rating at $360 target By Investing.com

Barclays kept an Equalweight on Tesla with a $360 price target vs. the current share price of $367.96 and a $1.38 trillion market cap. Barclays flagged materially higher capex risk — suggesting spending could exceed $20B and potentially be many multiples above a $50B bull-case figure — while Tesla targets a 1-terawatt project funded alongside SpaceX/xAI. Regulatory risk escalated as the NHTSA upgraded its probe to a detailed engineering analysis covering ~3.2 million vehicles; GLJ reiterated a Sell citing Full Self-Driving recall risk. Offsetting items include Stifel’s Buy call on strong automotive margins (two-year high in Q4 2025) and Goldman noting progress on Optimus robot hardware; balance-sheet metrics show more cash than debt (current ratio 2.16, debt/equity 0.18).

Analysis

Tesla’s stated move toward terawatt-scale power and humanoid robotics is not just a demand story for batteries and fabs — it is a multi-year capital allocation shock. Treat capex as a multi-decade liability: incremental spending that scales non-linearly (high fixed-cost, lumpy milestones) will compress free cash flow volatility and raise the probability the company will prioritize asset buildouts over near-term shareholder returns. That raises second-order winners in construction, industrial automation, and AI infrastructure where one-time capex orders and server purchases are sourced.

Regulatory escalation creates a conditional liquidity sink. An engineering-level probe typically unfolds over 6–18 months and can prompt recalls, warranty accruals, and reputational damage that hit margins and delay higher-return initiatives (robotaxi/Optimus). If capex overruns and regulatory costs converge within a 12-month window, funding pressure increases the chance of equity issuance or diverted internal transfers from related private entities, which would be asymmetric for shareholders.

Market positioning currently underweights the distributional risk: consensus seems willing to underwrite extreme multi-year optionality while underpricing near-term operational risks. That sets up asymmetric trade opportunities — hedge-able short exposure to capex/recall shocks funded by long exposure to AI/compute beneficiaries who win from the same strategic pivot. Time horizons matter: days-to-weeks for volatility trades around catalyst windows, 6–18 months for capital allocation / regulatory outcomes, and 2+ years for optionality on robotaxi/Optimus proofs of concept.

Key Decisions for Investors

• Initiate a directional hedge: Buy a 12-month TSLA put spread (buy 35% OTM, sell 60% OTM) sized to limit downside risk to <2% NAV. Thesis: protects against a 30%+ drawdown from capex + recall shocks; capped cost keeps payoff asymmetric (target 3–5x payoff if downside materializes).
• Pair trade (6–12 months): Short TSLA equity (3–5% NAV) and go long SMCI (3–5% NAV). Rationale: capture structural risk to capital-hungry EV build vs near-term AI/server demand tailwinds. Hedge: buy a 9–12 month TSLA call at ~20% notional to cap upside risk from a successful robotaxi headline.
• Income/vol strategy (30–90 days): Sell near-term TSLA calls into rallies (covered if you own or delta-hedged otherwise) to harvest elevated IV before next regulatory/earnings catalysts. Keep position size limited given tail risk; roll or unwind into put protection if IV spikes post-catalyst.
• Long optionality with cheap hedge (2+ years): Buy a 2-year TSLA LEAP call sized 25–50% of a short-term protective put exposure. This creates long convexity for multi-year robotaxi/Optimus success while funding protection against near-term operational/financial stress.
• Buy SMCI cash-secured puts (9–12 months, 20–30% OTM) to accumulate AI-infrastructure exposure on weakness. Risk: assignment and capital deployment; reward: acquiring a high-conviction beneficiary of incremental compute spend at a discount.